Loop Electrosurgical Excision Procedure for HIV+ Women More Likely to Clear High-Risk HPV Infection vs Cryotherapy for CIN

Article

A secondary analysis of a clinical trial indicated that women who were human immunodeficiency virus–positive and underwent loop electrosurgical excision procedure for cervical intraepithelial neoplasia had an increased likelihood of clearing high-risk human papillomavirus than women who underwent cryotherapy.

Women who were human immunodeficiency virus–positive and received loop electrosurgical excision procedure (LEEP) for grade 2 cervical intraepithelial neoplasia (CIN2) were more likely to clear high-risk human papillomavirus (hrHPV) than women who underwent cryotherapy over a 24-month period (HR, 1.40; 95% CI, 1.03-1.90; P = .03), according to results from the secondary analysis of a study (NCT01298596) published in JAMA Oncology.

At baseline, overall prevalence of any hrHPV was 92%, with specific hrHPV prevalence of 90% in the cryotherapy arm and 94% in the LEEP arm (P = .24). The most common types of hrHPV detected among patients were 16 (27%), 58 (27%), 35 (26%), 52 (20%), and 18 (17%).

“This secondary analysis of a [randomized clinical trial] supports the clinical benefits of LEEP over cryotherapy if this method is available and accessible in low- and middle-income countries,” the investigators wrote. “Testing for hrHPV after cervical treatment is useful in ruling out recurrent cervical disease among women living with HIV and could be administered as early as 6 months after treatment.”

Women living with HIV were recruited from the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya, and provided informed written consent to participate on the study. Eligibility criteria required that patients be aged 18 years or older, HIV positive, sexually active, not pregnant, and have an intact cervix.

According to World Health Organization International Agency for Research on Cancer categorization, 12 types of HPV were considered high risk, including type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 disease.

The main outcomes of this secondary analysis were hrHPV positivity and disease recurrence, which was defined as CIN2 or higher.

HIV-positive women were enrolled on the trial between June 2011 and September 2016, of whom 354 were confirmed to be CIN2-positive on colposcopy-directed biopsy. The population was divided evenly, with 177 women each receiving cryotherapy or LEEP treatment. Demographics between the cryotherapy and LEEP groups were similar, with most patients having a monthly household income of less than $150 per month (62% vs 64%; P = .79) and at least 2 years of antiretroviral treatment (ART) the time of enrollment (51% vs 57%; P = .20). Additionally, 29% of patients in the cryotherapy arm and 27% of patients in the LEEP arm were similarly immunocompromised, with CD4 counts less than 250 cells/mm3 (P = .75)

After 12 months of undergoing treatment, type-specific baseline hrHPV persistence was higher for women who underwent cryotherapy (61%) compared with those who underwent LEEP (49%; P = .04). Moreover, persistence was higher for the cryotherapy arm compared with LEEP treatment arm among those with hrHPV type 16 (69% vs 48%; P = .046) and type 51 disease (44% vs 12%; P = .04).

A notable number of women with type-specific hrHPV persistence at 12 months were found to have recurrent CIN2 positivity during the follow up period of 2 years. hrHPV persistence and recurrent CIN2 positivity was observed in patients who had a single type-specific hrHPV detection at enrollment (61%), hrHPV types 16 and/or 18 (48%), any type-specific hrHPV (42%), multiple type- specific hrHPV (32%).

Type-specific hrHPV persistence maintained a high and statistically significant association with CIN2-positive recurrence in multivariable analyses including treatment intervention and CD4 count (aHR, 4.70; 95% CI, 2.47-8.95; P <.001).

“Further study is needed to determine the cost-effectiveness of LEEP and the long-term implications of hrHPV persistence after treatment on cervical cancer and mortality among women living with HIV,” the investigators concluded.

Reference

Chung MH, De Vuyst H, Greene SA, et al. Human papillomavirus persistence and association with recurrent cervical intraepithelial neoplasia after cryotherapy vs loop electrosurgical excision procedure among HIV-positive women: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(10):1514-1520. doi:10.1001/jamaoncol.2021.2683

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content